SENORES PHARMACEUTICALS L

Develops, manufactures, and markets generic pharmaceutical formulations, primarily targeting the US through Abbreviated New Drug Applications (ANDAs) and a growing set of international emerging markets. The business is structured around two principal segments — Regulated Markets (which contributed 71% of Q1 FY27 revenue with 42% year-on-year growth and around 40% EBITDA margin), focused on US ANDA filings — and Emerging Markets (around 30% YoY growth in Q1 FY27, mid-teens EBITDA margin), covering countries such as Canada, Mexico, UK, UAE, Saudi Arabia, South Africa, Vietnam, Australia, and New Zealand. The ANDA portfolio has nearly doubled to 58 approved products (187 strengths) with 23 commercialized, and 39 molecules sit in the pipeline targeting markets of USD 740 million or more; 35 launches are planned over the next 18-20 months. Manufacturing runs out of a USFDA-approved facility in Vadodara acquired via Apnar Pharma (75% stake, with MHRA and Health Canada approvals) and a formulation development site at Chhatral, Gujarat, with an oral solids capacity expansion underway. Smaller revenue lines include an India branded generics business scaling to around 200 medical representatives and the Amerisyn joint venture for US federal/VA procurement. On the cost side, materials are the largest single P&L component at 18.1% of revenue, followed by employee costs at 17.7% and other operating expenses at 15.9%. AR · MarketPing reader · 2026-08-02

Revenue streams, as the annual report describes them. Regulated Markets (71%), Emerging Markets, India Branded Generics, Amerisyn JV (US Federal/VA). Growth-stage generic pharmaceuticals with R&D-led ANDA pipeline and integrated manufacturing

Exhibit 1: Financial summary, FY25–FY26 (all audited; no estimate years)